Veronica Moreno

[NEJM @NEJM]

Ischemic stroke, defined as a central nervous system injury caused by loss of blood flow, is most often due to arterial thromboembolism. Evaluation should include relevant blood tests and cardiovascular and cardiac investigations (seen in table). Learn more: https://t.co/bQSiiHnizV

[Julieta Rosales @J_Rosales_MD]

🔥🔥MeVO RCT summary ❌❌❌✅✅

#ISC2026
@SposatoL @WorldStrokeEd @SVINJournal @WorldStrokeEd @EdmontonStroke @StrokeAHA_ASA @ShadiYaghi2

[Fawaz Alotaibi @drfawaz120]

ISC 2026 Late-Breaking Trials—key highlights:
🔴 Acute: CHOICE-2, FASTEST, LAIS, LB035
🔵 Prevention: OCEANIC-STROKE, CREST-2
🟢 Hemorrhage: EMBOLISE

Stroke care continues to move toward more precise, evidence-based treatment. Which trial stood out to you?

#ISC26 #Stroke

[Circulation @CircAHA]

Meta-analysis of 5 RCTs (n=4,964): Adding antiplatelet therapy to anticoagulation in chronic coronary syndrome patients offers no benefit for MI, stroke, or MACE—but doubles major bleeding risk. Net clinical outcome significantly worse with dual pathway... https://t.co/qnTmEvmaVT

[Edmonton Stroke Program @EdmontonStroke]

#ISC2026 Day 3 Plenary Session. Roller coaster with MeVO today and new cerebroprotection molecule on the block @AHAScience @StrokeAHA_ASA

[Johanna Seiden, MD MPH @JohannaSeidenMD]

ATTENTION-LATE: IV TNK + EVT vs EVT Alone in BAO 4.5-24 hrs #ISC26 @StrokeAHA_ASA
- baseline NIHSS >10
- exclusion: pre-stroke mRS >2 or PC-aspects <5
- No diff in MRS 0-2 at 90 days between groups, consistent in subgroup analysis
-No diff in secondary efficacy/ safety outcomes

[Robert Regenhardt, MD, PhD @rwregen]

#DISTALS primary endpoint just presented at #ISC26! For #DMVO, #EVT with #Tigertriever 13 was associated with greater successful reperfusion at 24h without sICH! Long term clinical outcome are pending. @AHAScience @StrokeAHA_ASA @svinsociety @SVINJournal @SNISinfo

[Johanna Seiden, MD MPH @JohannaSeidenMD]

#ISC26 @StrokeAHA_ASA
ORIENTAL-MeVO: A positive trial in MeVO space shows that EVT within 24 hrs of sx onset among pts with moderate/high clinical severity improved 90-day functional outcomes without increasing mortality or sICH @RaulNogueiraMD

[Robert Regenhardt, MD, PhD @rwregen]

#ORIENTAL-MEVO just presented at #ISC26: #EVT within 24h for #MEVO with NIHSS >6 significantly improved 90d functional outcomes without increasing mortality or sICH among Chinese population! @AHAScience @StrokeAHA_ASA @svinsociety @SVINJournal @SNISinfo @JNIS_BMJ

[Shadi Yaghi @ShadiYaghi2]

Bleeding profile favoring DAPT over DOAC + antiplatelet in symptomatic ICAD. What works for CV disease may not work for cerebrovascular disease, c/w CAPTIVA
- advance medical tx by adding Factor XIa, PCSK9, GLP.
- select patients for EVT based on perfusion
https://t.co/wAnHhGvUPp

[Ingrid Marques @marquesingrid12]

Stroke Prevention in Moyamoya Syndrome #ISC26
Cilostazol: The New Celebrity in Stroke?
✅️ 23% reduction in mortality
✅️ Incrased CBF and cognition vs clipidogrel
✅️ 6% ischemic recurrence at 5 years
@StrokeAHA_ASA

[Victor J. Del Brutto, MD, MS, FAHA @vdelbrutto]

#ISC26 #OPTIONStudy adds further evidence supporting thrombolysis with TNK in the extended 4.5–24h window among cselected non-LVO non-EVT patients with salvageable tissue.

[Robert Regenhardt, MD, PhD @rwregen]

#CREST-2 Neither CAS nor CEA for asymptomatic stenosis demonstrated cognitive benefit #ISC26 @AHAScience @StrokeAHA_ASA @SVINJournal @svinsociety

[Victor J. Del Brutto, MD, MS, FAHA @vdelbrutto]

#ISC26 #TNKplus: Along with #TIMELESS, patients with MCA LVO and salvageable tissue presenting 4.5–24h from onset, TNK prior to immediate (median 26m) EVT does not improve outcomes compared with EVT alone.

[Seemant Chaturvedi @ChaturvediNeuro]

CREST H shows no improvement in cognitive function in pts with asymptomatic stenosis and evidence of hemodynamic impairment. Important information for patients ⁦@ESOstroke⁩ ⁦@WorldStrokeOrg⁩ ⁦@AANmember⁩

[Robert Regenhardt, MD, PhD @rwregen]

#EMBOLISE 2 (non-surgical cohort) results presented at #ISC26 showing #MMA embolization with #Onyx is superior to observation in reducing the risk of surgical rescue or deteriorated clinical outcome! @AHAScience @StrokeAHA_ASA @svinsociety @SVINJournal @SNISinfo @JNIS_BMJ

[Dawn Meyer PhD,FNP-C,FAHA @UCSDStroke]

No benefit with addition of TNK to EVT in basilar artery occlusion in the ATTENTION LATE trial. Sharing results of "negative" trials is critical to understanding and building on knowledge gained!
#ISC2026 #negativeclinicaltrial #attentionlate @StrokeAHA_ASA

[Johanna Seiden, MD MPH @JohannaSeidenMD]

What's New in IVT? Relative and Absolute Contraindications #ISC26 @StrokeAHA_ASA

[JAMA @JAMA_current]

In patients with non–large-vessel occlusion stroke and salvageable tissue, tenecteplase extended to 24 hours improved outcomes compared with standard care but increased bleeding risk.

#ISC26 @AHAScience

https://t.co/JWRN5S9QmQ

[Edmonton Stroke Program @EdmontonStroke]

#ISC2026 day 2, great day for secondary stroke prevention and non-LVO acute ischemic stroke presenting after 4.5 h and have mismatch on perfusion @AHAScience @StrokeAHA_ASA